key: cord-0887372-4sck9f3j
authors: Joseph, Jeswin; Karthika, T.; Das, V.R. Akshay; Raj, V. Stalin
title: Epigallocatechin-3-gallate (EGCG): a potential molecule for the development of therapeutics against emerging SARS-CoV-1, MERS-CoV and SARS-CoV-2 coronaviruses
date: 2021-05-27
journal: J Glob Antimicrob Resist
DOI: 10.1016/j.jgar.2021.05.005
sha: 139a45035c93d9f2b86bbfbef2d48f2d4a7f9037
doc_id: 887372
cord_uid: 4sck9f3j

nan

Epigallocatechin-3-gallate (EGCG), the primary component in green tea (Camellia sinensis), has unique 3-galloyl and 5'-OH groups critical for binding to envelope glycoproteins and inhibiting the cellular entry of several viruses, including Zika virus, hepatitis C virus and influenza virus [2] . In this study, we report the antiviral properties of EGCG against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. EGCG 2 EGCG and epicatechin (EC) are polyphenolic flavonoids (Fig. 1a ,b) predominantly found in green tea and have a wide range of medicinal benefits [2] . To investigate the antiviral activity of EGCG and EC against coronaviruses, in this study we first treated Vero E6 cells, susceptible to SARS-CoV-1, SARS-CoV-2 [3] and MERS-CoV Our data indicate that EGCG inhibits the entry of CoV-PVs without inducing cytotoxicity.

3 Next, to test whether EGCG interacts with the spike protein of SARS-CoV-1, SARS-CoV-2 and MERS-CoV, we generated recombinant RBD proteins and performed fluorescence emission spectrophotometry. We incubated RBD proteins with varying concentrations of EGCG (25-100 M) at either 25 °C or 37 °C and measured the emission spectra. We observed a gradual decrease in fluorescence emission of the RBD proteins treated with EGCG (Fig. 1f) , consistent with previous reports showing that interaction of EGCG with the envelope proteins of herpes simplex virus 1 or reovirus decreases the fluorescence emission of these proteins [5] . These data indicate that EGCG interacts with the RBD of CoVs, and a complete quenching was observed at 100 µM of EGCG at 37 °C (Fig. 1f) , which correlates with our CoV-PV infection (Fig. 1d) . Next, we ruled out that the observed inhibition was due to protein degradation by western blot analysis (Fig. 1g) , which indicates that EGCG could bind to the RBD of CoVs without affecting its stability.

Furthermore, to check whether the binding of EGCG with the RBD inhibits the spikereceptor interaction, we performed a binding assay on HEK293T cells expressing ACE2/DPP4. RBD proteins were incubated independently with either EGCG or EC and the complex was then allowed to bind on the surface of the cells. Binding of RBD proteins was analysed by confocal microscopy and fluorescence-activated cell sorting (FACS). EC-treated RBD did bind, but EGCG-treated proteins did not bind on their respective receptors (Fig. 1h) . Moreover, no RBD-bound cells were observed with EGCG-treated proteins in either of the assays (Fig. 1i, j) . These data clearly show that EGCG-bound RBD protein is unable to interact with either ACE2 or DPP4.

We speculate that inhibition of viral entry by EGCG might be due to binding to the 

Coronavirus biology and replication: implications for SARS-CoV-2

A review of the antiviral role of green tea catechins

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

A small molecule inhibits virion attachment to heparan sulfate-or sialic acid-containing glycans

E-mail address: stalin@iisertvm.ac.in (V. Stalin Raj)

Supplementary material related to this article can be found, in the online version.